Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MYEOV (myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas))

Identity

Other namesOCIM
HGNC (Hugo) MYEOV
LocusID (NCBI) 26579
Location 11q13.3
Location_base_pair Starts at 69061622 and ends at 69064754 bp from pter ( according to hg19-Feb_2009)  [Mapping]
Local_order 350 kb centromeric of cyclin D1.
Note Detected by application of the NIH/3T3 tumorigenicity assay. However MYEOV cDNA was not positive in NIH/3T3 assay.

DNA/RNA

Note The MYEOV gene was originally isolated by the application of the NIH/3T3 tumorigenicity assay with DNA from a gastric carcinoma. The chromosomal region 11q13 is frequently associated with genetic rearrangements in a large number of human malignancies, including B-cell malignancies and overexpression of MYEOV is frequently observed in breast tumors and oral, esophageal squamous cell carcinomas and multiple myeloma. The presence of functional domains such as RNP-1 (motif typical of RNA binding protein) and the studies of the short hydrophobic regions and of the C-terminal leucine/isoleucine tail showed that MYEOV might be directed to the membrane. MYEOV small interfering RNA (siRNA) decreased proliferation of gastric cancer cells, colon cancer cell lines and multiple myeloma cells in vitro.
 
Description 2 exons; 3,5 kb transcript represents unspliced mRNA.
Transcription Main transcript 2,8 kb (broad band because of alternative splice products); minor transcript 3,5 kb; coding sequence 313 or 255 amino acids. In normal tissues hardly any expression detectable. High expression in a subset of multiple myeloma cell lines with a t(11;14)(q13;q32) and in breast tumors and esophageal squamous cell carcinomas with or without 11q13 amplification.
Pseudogene No pseudogenes have been reported for MYEOV.

Protein

Description 313 or 255 amino acids; contains one RNP-1 motif and 6 regions that might function as a transmembrane domain. Leucine-rich stretch at C-terminal.
Expression 5' UTR inhibits efficient translation of the protein.
Localisation In endoplasmic reticulum and mitochondria.
Homology No known homology.

Implicated in

Entity t(11;14)(q13;q32)
Disease Subset of multiple myeloma cell lines with t(11;14)(q13;q32).
Cytogenetics MYEOV overexpression due to juxtaposition to the 5' enhancer or the most telomeric 3' enhancer of the immunoglobulin heavy chain (IgH).
  
Entity 11q13 amplification and/or overexpression
Disease Breast cancer; esophageal squamous cell carcinomas.
Prognosis MYEOV DNA amplification correlated with estrogen and progesterone receptor-positive cancer, invasive lobular carcinoma type and axillary nodal involvement. In contrast to Cyclin D1 amplification, no association with disease outcome could be found.
  
Entity Multiple myeloma
Prognosis In a cohort of 171 myeloma patients, patients with MYEOVabsent MMC have an increased event-free survival compared to patients with MYEOVpresent MMC, after high-dose therapy and stem cell transplantation and a trend for increased overall survival. In a Cox proportional hazard model, MYEOV expression in MMC is predictive for event-free survival for patients independently of International Staging System stage, t(4;14) translocation, albumin, or B2M serum levels. In a second independent cohort of 208 patients (LR-TT3, from the University of Arkansas for Medical Sciences (Little Rock, AR, USA)), MYEOV had a "present" call in MMCs of 73% of patients. Patients with MYEOVabsent MMCs had a significant better overall survival in the LR-TT3 cohort.
Oncogenesis In a cohort of 171 patients, MMC of 79% of the patients with newly diagnosed MM express MYEOV gene. A treatment with 5-aza-2'-deoxycytidine of 2 MYEOVabsent myeloma cell lines induced MYEOV expression without affecting that in the MYEOVpresent myeloma cells. MYEOV siRNA did not significantly induce apoptosis in myeloma cell lines, but it blocked the cell cycle entry into the S-phase.
  
Entity Colon cancer
Oncogenesis Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of colon cancer cell lines in vitro. Furthermore, in colon cancer, MYEOV stimulates colorectal cancer cell migration in vitro. MYEOV expression is enhanced by PGE2 treatment in colorectal cancer cells.
  
Entity Gastric cancer
Oncogenesis Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation and invasion of gastric cancer cells in vitro.
  
Entity Neuroblastoma
Oncogenesis MYEOV is a candidate gene target in neuroblastoma that was identified by chromosomal gain 11q13 through SNP analysis. MYEOV expression was analyzed in 55 neuroblastoma samples including 25 cell lines. MYEOV was shown to be upregulated in 11 out of 25 neuroblastoma cell lines and 7 out of 20 fresh tumors. Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of neuroblastoma cell line in vitro.
  
Entity Oral squamous cell carcinoma
Oncogenesis Gain of 11q13 was significantly associated with cervical lymph node metastasis in oral squamous cell carcinoma (54 patients included in the study). Copy number amplification of MYEOV is associated with cervical lymph node metastasis in oral squamous cell carcinoma. Lymph node metastasis is associated with a significant decrease of 5-years survival in oral squamous cell carcinoma.
  

External links

Nomenclature
HGNC (Hugo)MYEOV   7563
Entrez_Gene (NCBI)MYEOV  26579  myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)
Cards
AtlasMYEOVID395
GeneCards (Weizmann)MYEOV
Ensembl (Hinxton)ENSG00000172927 [Gene_View]  chr11:69061622-69064754 [Contig_View]  MYEOV [Vega]
AceView (NCBI)MYEOV
Genatlas (Paris)MYEOV
euGene (Indiana)26579
SOURCE (Stanford)NM_138768
Genomic and cartography
GoldenPath (UCSC)MYEOV  -  11q13.3   chr11:69061622-69064754 +  11q13   [Description]    (hg19-Feb_2009)
EnsemblMYEOV - 11q13 [CytoView]
Mapping of homologs : NCBIMYEOV [Mapview]
OMIM605625   
Gene and transcription
Genbank (Entrez)AJ223366 AJ223366 AK026148 AK290121 BC011815
RefSeq transcript (SRS)NM_138768
RefSeq transcript (Entrez)NM_138768
RefSeq genomic (SRS)AC_000143 NC_000011 NT_167190 NW_001838026
RefSeq genomic (Entrez)AC_000143 NC_000011 NT_167190 NW_001838026
Consensus coding sequences : CCDS (NCBI)MYEOV
Cluster EST : UnigeneHs.523848 [ SRS ] Hs.523848 [ NCBI ]
Alternative Splicing : Fast-db (Paris)11061
Alternative Splicing GalleryENSG00000172927
Gene ExpressionMYEOV [ NCBI-GEO ]   MYEOV [ EBI - ARRAY_EXPRESS ]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ96EZ4 (SRS) Q96EZ4 (Uniprot)
With graphics : InterProQ96EZ4
Splice isoforms : SwissVarQ96EZ4(Swissvar)
Related proteins : CluSTrQ96EZ4
Domain families : Pfam (SRS)
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Blocks (Seattle)Q96EZ4
Human Protein AtlasENSG00000172927
HPRD16130
IPIIPI00305042   IPI01015112   
Protein Interaction databases
DIP (DOE-UCLA)Q96EZ4
IntAct (EBI)Q96EZ4
FunCoupENSG00000172927
REACTOMEMYEOV
BioGRIDMYEOV
InParanoidQ96EZ4
Interologous Interaction database Q96EZ4
Polymorphism : SNP, mutations, diseases
SNP Single Nucleotide Polymorphism (NCBI)MYEOV
SNP (GeneSNP Utah)MYEOV
SNP : HGBaseMYEOV
Genetic variants : HAPMAPMYEOV
Somatic Mutations in Cancer : COSMICMYEOV 
CONAN: Copy Number AnalysisMYEOV 
Mutations and Diseases : HGMDMYEOV
OMIM605625   
GENETests605625   
Disease Genetic AssociationMYEOV
Huge Navigator MYEOV [HugePedia]  MYEOV [HugeCancerGEM]
Genomic VariantsMYEOV
snp3D : Map Gene to Disease26579
General knowledge
Homologs : HomoloGeneMYEOV
Homology/Alignments : Family Browser (UCSC)MYEOV
Phylogenetic Trees/Animal Genes : TreeFamMYEOV
Chemical/Protein Interactions : CTD26579
Chemical/Pharm GKB GenePA31362
Clinical trialMYEOV
Cancer Resource (Charite)ENSG00000172927
Ontology : AmiGO
Ontology : EGO-EBI
Other databases
Probes
Probes : ImagenesMYEOV Related clones (RZPD - Berlin)
Litterature
PubMed14 Pubmed reference(s) in Entrez
PubGeneMYEOV
iHOPMYEOV

Bibliography

Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
Janssen JW, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E.
Blood. 2000 Apr 15;95(8):2691-8.
PMID 10753852
 
MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer.
Janssen JW, Cuny M, Orsetti B, Rodriguez C, Valles H, Bartram CR, Schuuring E, Theillet C.
Int J Cancer. 2002 Dec 20;102(6):608-14.
PMID 12448002
 
MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas.
Janssen JW, Imoto I, Inoue J, Shimada Y, Ueda M, Imamura M, Bartram CR, Inazawa J.
J Hum Genet. 2002;47(9):460-4.
PMID 12202983
 
Net1 and Myeov: computationally identified mediators of gastric cancer.
Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, O'Keane C, Doran P, MacMathuna P.
Br J Cancer. 2006 Apr 24;94(8):1204-12.
PMID 16552434
 
ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion.
Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, Keane CO, Brady HR, Doran PP, MacMathuna P.
Biochem Biophys Res Commun. 2006 Jun 23;345(1):216-21. Epub 2006 Apr 27.
PMID 16678123
 
MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2.
Lawlor G, Doran PP, MacMathuna P, Murray DW.
J Exp Clin Cancer Res. 2010 Jun 22;29:81.
PMID 20569498
 
MYEOV is a prognostic factor in multiple myeloma.
Moreaux J, Hose D, Bonnefond A, Reme T, Robert N, Goldschmidt H, Klein B.
Exp Hematol. 2010 Dec;38(12):1189-1198.e3. Epub 2010 Sep 18.
PMID 20854874
 
Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma.
Sugahara K, Michikawa Y, Ishikawa K, Shoji Y, Iwakawa M, Shibahara T, Imai T.
Int J Oncol. 2011 Oct;39(4):761-9. doi: 10.3892/ijo.2011.1094. Epub 2011 Jun 22.
PMID 21701773
 
Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma.
Takita J, Chen Y, Okubo J, Sanada M, Adachi M, Ohki K, Nishimura R, Hanada R, Igarashi T, Hayashi Y, Ogawa S.
Cancer Sci. 2011 Sep;102(9):1645-50. doi: 10.1111/j.1349-7006.2011.01995.x. Epub 2011 Jul 3.
PMID 21624008
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written12-2002Johannes WG Janssen
Janssen Institut fur Humangenetik Universitatsklinikum Heidelberg Im Neuenheimer Feld 328 D-69120 Heidelberg, Germany
Updated10-2011Jérôme Moreaux
INSERM U1040, institut de recherche en biotherapie, CHRU Saint Eloi, 80 Av Augustain Fliche, 34295 Montpellier CEDEX 5, France

Citation

This paper should be referenced as such :
Janssen JWG . MYEOV (myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)). Atlas Genet Cytogenet Oncol Haematol. December 2002 .
URL : http://AtlasGeneticsOncology.org/Genes/MYEOVID395.html
Moreaux J . MYEOV (myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)). Atlas Genet Cytogenet Oncol Haematol. October 2011 .
URL : http://AtlasGeneticsOncology.org/Genes/MYEOVID395.html

This paper is referenced by INIST as such :
   [ Bibliographic record ]
http://documents.irevues.inist.fr/bitstream/2042/37928/1/12-2002-MYEOVID395.pdf   [ Bibliographic record ]

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Apr 28 15:00:19 CEST 2012
Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.